Clinical trials

Hypoparathyroidism

Hypoparathyroidism is a rare medical condition caused by full or partial inability of the body to produce the parathyroid hormone (PTH). This hormone regulates calcium absorption and use, and its deficiency leads to low blood calcium (hypocalcemia). Hypoparathyroidism is classified as an “orphan disease”, with about 200,000 patients, globally.

Because hypoparathyroidism is a chronic condition, people who have it must take daily calcium supplement in doses that can be remarkably high and reach up to 10,000 mg/day to maintain normal calcium concentration in the blood.

A clinical study conducted in Rambam Hospital  included 9 patients, each on a different stable dose of calcium. In the course of the study, each patient’s calcium was gradually replaced with amorphous calcium carbonate (ACC). The final ACC dose was half of the patient’s previous dose of calcium, yet their blood calcium levels remained normal.3

The results of this study prove that the total daily dose of calcium can be reduced at least by half when using ACC compared to other calcium supplements. This can be explained by ACC’s exceptional solubility and bioavailability.

The results of the study have been submitted to the FDA, which gave its approval to continue clinical studies (Phase 2/3) in humans.

Skip to content